How to Draft an Irresistible Response to an FDA 483 Observation

For any pharmaceutical manufacturer, having an open FDA 483 is one of the more difficult situations to experience. The inspection has concluded; the inspector has issued the objectionable conditions, and it is now up to senior management to convince the agency that the company understands the problems and has the capability of being able to fix those issues.

In my experiences, the quality of the response is usually more important to an organization than the number of observations received. I have seen organizations receive many observations, but they have not experienced any additional regulatory enforcement action due to having submitted a thorough, scientific and transparent response. On the contrary, I have also seen organizations that received only a few observations, later received Warning Letters or other regulatory actions due to the fact their response was defensive, incomplete or did not provide sufficient evidence to convince the agency of their willingness to correct the problems.

An effective FDA 483 response is not intended to be a negotiation document. Rather, it is intended to be a reflection of the organization's quality culture, leadership commitment and its ability to effectively manage pharmaceutical risk.

Understanding FDA Form 483

When investigators notice conditions during an inspection that imply that there may be a failure to comply with Current Good Manufacturing Practices (cGMP), they may issue an FDA Form 483 (Inspectional Observations).

The observations noted on a Form 483 represent findings based on the investigator's inspection and allow the facility an opportunity to respond with planned corrective action prior to the FDA's decision making on any possible future regulatory actions. The response to an FDA Form 483 must include sufficient information to satisfy the reviewers that:
- The observations have been acknowledged
- Product quality risks have been assessed
- The root cause(s) have been determined
- Corrective action(s) being implemented will be sustained over time
- The same deviation will not occur in the future

Why the FDA 483 Response is Critical

A response submitted to the FDA within fifteen business days will be viewed more favorably than those submitted after the designated time frame, for purposes of the FDA's review. A satisfactory response will demonstrate:
- Management's commitment
- The maturity of the quality system
- Scientifically-based decision-making
- Effective management of risk
- A culture of compliance

A less-than-satisfactory response may result in:
- Warning letters
- Reinspection
- Import alerts
- Increased regulatory scrutiny
- Loss of customer confidence
Consequently, the response to an FDA 483 should be considered to be a strategic quality document as opposed to simply a routine exercise in meeting compliance requirements.

First Actions After Receiving a 483

The timeframe of the first 24 to 48 hours is crucial. Organizations should spend that time understanding the observations fully before drafting a response. Some reasonable actions organizations may want to take during that timeframe can be:

• Creation of a cross-functional response team
• Reviewing the investigator's notes
• Gathering any documentation that supports your response
• Determining effects to products and others
• Taking immediate corrective actions when appropriate
• Informing senior management of the receipt of the 483

Taking quick actions conveys to the organization your compliance commitment and will help preserve critical evidence.

Understanding the Root Cause of the Observation

A common mistake I see is the company responds only to the text of the specific observation instead of truly understanding what the compliance concern is behind the observation. An observation related to "incomplete" investigations could also be viewed as other issues related to deficiencies:

• Quality Oversight
• Root Cause Analysis
• CAPA Effectiveness
• All Training Programs
• Management Reviews

The view that you only address what is actually visible will also not satisfy what the regulators are expecting.

Structure of an Effective FDA 483 Response

Your response should be logically structured so that the reviewer can comprehend the problem and solution. Your response should contain the following:
1. Observation acknowledgment
2. Issue understanding
3. Immediate corrective actions
4. Cause-solution analysis
5. Product-impact analysis
6. CAPA
7. Implementation timeline
8. Supportive documentation
Be sure that each of these areas shows confidence, that you have adequately responded to the problem.

Begin with Professional Acknowledgement

Avoid using accusatory terms or language. Instead, thank the investigator for performing the inspection and his observations.
Example:
"We greatly appreciate your observations made during the inspection and have done an abundant amount of follow-up work about the subject. The company will implement viable, enduring corrective actions, thus enhancing our drug quality system."

This beginning creates a collaborative interaction.

Perform a Thorough Root Cause Analysis

Another key indicator of the quality of the response will be the level of detail in the root cause analysis. The simple statement "Personnel error" or "Procedure not followed" is almost never sufficient. The organization needs to determine the reason for the error. The following represent some potential root causes of an error:

• Insufficient training
• Poorly designed procedure
• Lack of supervision
• Poor oversight of quality
• Complexity of process
• Limitations of resources

In my experience, organizations that are able to identify true systemic causes are typically much more successful at preventing recurrence of observations.

Include Immediate Corrective Actions

FDA assessors will want to know what immediate actions were taken following the observation. Examples of immediate actions may include:

• Quarantining product
• Suspending process
• Performing additional testing
• Inspecting equipment
• Reviewing documentation
• Retraining of employee

Immediate actions will provide assurance of control while long-term improvements are executed.

Conduct a Product Impact Assessment

Significant observations will always include a review of the quality of the product and the safety of the patient. One consideration with regards to product impact assessments is:

• Will the released batches be impacted?
• Will there be any products on the shelf or out in the marketplace?
• Will additional testing to the product(s) be needed?
• Will there be anything to consider when deciding to recall?
• Will customers be impacted?

Science-based and fully documented Product Impact Assessments are necessary.

Create an effective CAPA

The CAPA section can be the determination to whether the answer is satisfactory, as defined by the FDA. To do this you will have to do both the needed corrections and prevent future reoccurrence of producing nonconforming product. Some examples of actions you could take would be:

• Revising your SOP
• Redesigning your processes
• Adding automation where feasible
• Adding additional verifications to processes
• Improving your training program
• Improving your management review process

Every CAPA must include:

• Person assigned responsibility
• Date of completion
• Method of verification of effectiveness

Evidence to Support Each Statement

A frequent weakness seen with FDA responses is that in many cases there’s no supporting evidence to back up commitments. If available, please include:

• SOPs (updated)
• Training Records
• Investigation Reports
• Validation Summaries
• Risk Assessments
• Photographs
• CAPA Plans

Providing objective evidence adds significantly to the credibility of your response.

Include Realistic Timelines

Many organizations make promises with unrealistic timelines so as not to alienate the regulatory body. In my experience, this creates another set of compliance issues because you are unable to meet these commitments.
Instead:

• Complete your critical actions right away.
• Include realistic timelines to implement your initiatives.
• Communicate clearly about your long-range projects.
• Where applicable, list milestone dates.

Confidently fulfilling commitments would help create regulatory trust.

Writing an Effective FDA 483 Response

The best strategy when writing FDA 483 responses is to be:

• Clear
• Concise
• Objective
• Professional
• Based on facts

Do not use

• Emotional language
• Defensive arguments
• Unsubstantiated opinions
• Excessive technical jargon

The purpose of writing a response is to show competency, not to persuade through rhetorical means.

Common Mistakes that Weaken FDA 483 Responses

There are a variety of mistakes that are frequently seen in FDA 483 response letters and greatly decrease the response letter's effectiveness. Frequent areas of mistake:

• Blame the individual
• Superficial root cause
• Failure to see systemic issues
• Vague CAPA
• Failure to assess product impact
• No evidence provided
• Using generic templates

These weaknesses often result in additional regulatory concern.

Role of Senior Management

The senior managers must have an active role in preparing responses. There is evidence of leadership participation:

• Shows commitment to compliance
• Provides resource allocations
• Holds their staff accountable
• Establishes a culture of quality

The strongest responses will reflect "ownership" throughout the organization, not just by QA.

Monitoring After Submission

Submitting your response is only the beginning. Organizations should:

• Monitor the progress of their CAPA's
• Verify that they are effective
• Complete all commitments made
• Preserve documentation of implementation
• Prepare for re-inspection

FDA investigators may use the responses to verify whether the organization had completed all commitments as described in their response.

Creating a Culture of Quality Beyond the Response

An FDA Form 483 is not just an isolated compliance event, but should provide an opportunity for organizations to use the observations made to improve:

• The quality of investigations
• Risk management
• The quality of documentation practices
• Management oversight
• Employee training and development

Organizations that are focused on continuous improvement typically have fewer occurrences of repeated observations and stronger inspection outcomes.

Best Practices for an Effective Response to FDA Form 483

Successful organizations in the pharmaceutical industry consistently utilize a number of core principles. The following is a list of best practices which should be adhered to:

1. Respond within 15 business days of receipt of the FDA Form 483.
2. Conduct root cause analysis thoroughly and in a timely fashion.
3. Provide objective evidence to support your findings and corrective actions.
4. Develop measurable Corrective Action/Preventive Action (CAPA).
5. Evaluate the scientific impact of corrective actions on product(s).
6. Provide realistic timeframes for implementation of CAPA.
7. Verify the effectiveness of CAPA prior to closure.
8. Showcase management’s visible commitment to creating a quality culture.

These practices will give assurance that the organization is capable of achieving sustainable compliance with Good Manufacturing Practices (GMPs).

Effective responses to FDA 483s require much more than simply responding to inspectional observations. They represent a chance to display scientific thought processes; quality leadership, and maturity of the organization. A carefully prepared response will include acknowledging the deficiency openly, identifying systemic causes and providing objective evidence of each commitment of sustainability of corrective actions taken.

From my experience, companies that are transparent when responding to FDA observations, with true quality improvement intentions, frequently enhance the quality systems within the pharmaceutical industry and develop credibility within the regulatory agencies on a long-term basis. A persuasive response to the FDA 483 does not make the least argument; rather, it proves that the company recognizes its obligation to maintain the highest levels of product quality and patient safety.

Regulatory References

1. FDA Form 483 Frequently Asked Questions
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
2. FDA Investigations Operations Manual (IOM)
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/investigations-operations-manual
3. FDA Quality Systems Approach to Pharmaceutical cGMP Regulations
https://www.fda.gov/media/71023/download
4. ICH Q10 Pharmaceutical Quality System
https://database.ich.org/sites/default/files/Q10_Guideline.pdf
5. EU GMP Guidelines Volume 4
https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

Share

Tweet

Share

Pin it

Share